Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study

被引:0
作者
Dimitrios Alexopoulos
Nikolaos Barampoutis
Vasileios Gkizas
Chrysoula Vogiatzi
Grigorios Tsigkas
Nikolaos Koutsogiannis
Periklis Davlouros
George Hahalis
Sven Nylander
Guido Parodi
Ioanna Xanthopoulou
机构
[1] Patras University Hospital,Department of Cardiology
[2] Rion,Cardiovascular and Thoracic Department
[3] AstraZeneca R&D,undefined
[4] Careggi Hospital,undefined
来源
Clinical Pharmacokinetics | 2016年 / 55卷
关键词
Percutaneous Coronary Intervention; Prasugrel; Ticagrelor; Primary Percutaneous Coronary Intervention; Bivalirudin;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:359 / 367
页数:8
相关论文
共 129 条
[1]  
Alexopoulos D(2014)Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction Am J Cardiol 113 2064-2069
[2]  
Xanthopoulou I(2012)ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2569-2619
[3]  
Goudevenos J(2013)ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 e78-e140
[4]  
Steg PG(2008)Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction Thromb Res 122 776-781
[5]  
James SK(2012)FABOLUS PRO Investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial J Am Coll Cardiol Interv 5 268-277
[6]  
Atar D(2012)Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST elevation myocardial infarction Circ Cardiovasc Interv 5 797-804
[7]  
Badano LP(2013)Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI study J Am Coll Cardiol 61 1601-1606
[8]  
Blömstrom-Lundqvist C(2013)Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI J Am Coll Cardiol 62 940-941
[9]  
O’Gara PT(2014)Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study Am Heart J 167 909-914
[10]  
Kushner FG(2014)Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamic study Circ Cardiovasc Interv 7 233-239